SG11201809221WA - Administration of berberine metabolites - Google Patents

Administration of berberine metabolites

Info

Publication number
SG11201809221WA
SG11201809221WA SG11201809221WA SG11201809221WA SG11201809221WA SG 11201809221W A SG11201809221W A SG 11201809221WA SG 11201809221W A SG11201809221W A SG 11201809221WA SG 11201809221W A SG11201809221W A SG 11201809221WA SG 11201809221W A SG11201809221W A SG 11201809221WA
Authority
SG
Singapore
Prior art keywords
international
rayburn
sam
april
pct
Prior art date
Application number
SG11201809221WA
Inventor
Ryan Lowery
Jacob Wilson
Shawn Wells
Brian Underwood
Chistopher Harding
Terry LaCore
Original Assignee
Keto Patent Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keto Patent Group Inc filed Critical Keto Patent Group Inc
Publication of SG11201809221WA publication Critical patent/SG11201809221WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)

Abstract

60 14) 104104 4:500: mg 013.: 250 niF,,DH.BB 5tia . fag I3HBp 14S (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 October 2017 (26.10.2017) WIPO I PCT omit IIl mum o mo IIV Eno iflo oimIE (10) International Publication Number WO 2017/184789 Al (51) International Patent Classification: A61K 31/43 75 (2006.01) A61K 31/23 (2006.01) A61K 31/19 (2006.01) (21) International Application Number: PCT/US2017/028466 (22) International Filing Date: 19 April 2017 (19.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/324,794 19 April 2016 (19.04.2016) US 15/491,933 19 April 2017 (19.04.2017) US (71) Applicant: KETO PATENT GROUP, INC. [US/US]; 901 Sam Rayburn Higway, Melissa, TX 75454 (US). (72) Inventors: LOWERY, Ryan; 3517 Harken Circle, Tam- pa, FL 33607 (US). WILSON, Jacob; 110 S Matanzas Ave., Tampa, FL 33609 (US). WELLS, Shawn; 2504 Lincolnshire Lane, Lewisville, TX 75056 (US). UNDER- WOOD, Brian; 901 Sam Rayburn Highway, Melissa, TX 75454 (US). HARDING, Chistopher, N.; 2155 S. Ocean Blvd #16, Delray Beach, FL (US). LACORE, Terry; 901 Sam Rayburn Highway, Medlissa, TX 75454 (US). (74) Agent: DAHM, Elizabeth, Philip; Ferguson Braswell Fraser Kubasta PC, 2500 Dallas Parkway, Suite 600, Plano, TX 75093 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ADMINISTRATION OF BERBERINE METABOLITES Figure 1 (57) : In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be ad- ministered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds. [Continued on next page] WO 2017/184789 Al MIDEDIMOMOIDEIROIDEMOMOHOHOMEHOMEMOIMIE TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3))
SG11201809221WA 2016-04-19 2017-04-19 Administration of berberine metabolites SG11201809221WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324794P 2016-04-19 2016-04-19
PCT/US2017/028466 WO2017184789A1 (en) 2016-04-19 2017-04-19 Administration of berberine metabolites
US15/491,933 US10278961B2 (en) 2016-04-19 2017-04-19 Administration of berberine metabolites

Publications (1)

Publication Number Publication Date
SG11201809221WA true SG11201809221WA (en) 2018-11-29

Family

ID=60039309

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809221WA SG11201809221WA (en) 2016-04-19 2017-04-19 Administration of berberine metabolites

Country Status (7)

Country Link
US (1) US10278961B2 (en)
EP (1) EP3445358B1 (en)
AU (2) AU2017253110A1 (en)
CA (1) CA3021639A1 (en)
MX (1) MX2018012800A (en)
SG (1) SG11201809221WA (en)
WO (1) WO2017184789A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11026929B2 (en) * 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
CA3118317A1 (en) * 2018-10-29 2020-05-07 Keto Patent Group, Inc. Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
AU2020341711A1 (en) * 2019-09-05 2022-03-03 Arbor Biotechnologies, Inc. Novel CRISPR DNA targeting enzymes and systems
CA3195029A1 (en) * 2020-10-21 2022-04-28 Qiru FAN Methods for improving exercise performance and endurance thereof
WO2023081409A1 (en) * 2021-11-04 2023-05-11 Keto Patent Group, Inc. Administration of berberine metabolites

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1759834B (en) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
CN101153039B (en) * 2006-09-30 2010-12-01 中国科学院上海药物研究所 13, 13a- dihydro berberine derivant and pharmaceutical composition
US9510220B2 (en) 2012-03-28 2016-11-29 Lg Electronics Inc. Method for measuring channel using tracking reference signal in wireless communication system and device using same
KR102499654B1 (en) * 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 Compositions and methods for producing elevated and sustained ketosis
WO2015063140A1 (en) * 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Also Published As

Publication number Publication date
MX2018012800A (en) 2019-09-04
AU2017253110A1 (en) 2018-11-15
AU2023200826A1 (en) 2023-03-09
WO2017184789A1 (en) 2017-10-26
US10278961B2 (en) 2019-05-07
CA3021639A1 (en) 2017-10-26
EP3445358B1 (en) 2023-11-15
US20170296520A1 (en) 2017-10-19
EP3445358A1 (en) 2019-02-27
EP3445358A4 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
SG11201809211QA (en) Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
SG11201809221WA (en) Administration of berberine metabolites
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201900975XA (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201408324QA (en) Pyridinone and pyridazinone derivatives
SG11201804577RA (en) Fgf21 variants
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201408198QA (en) Jumper tube locking assembly and method
SG11201900651PA (en) Combination of fxr agonists
SG11201804587QA (en) Isoindole compounds
SG11201903326RA (en) Liposomal formulation for use in the treatment of cancer
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201805755SA (en) Methods of administering hepcidin
SG11201809561WA (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment